கடுமையான முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Norway Oncoinvent AS: Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin Norway Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round syndicated by existing investors Hadean Ventures, Geveran, RADFORSK Investeringsstiftelse, Sundt, Must Invest, Canica, MP Pensjon and Watrium. The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company s proprietary targeted radiotherapy

Jana alfheimCourtney turianoKostenloser wertpapierhandelRoyh larsenIngrid teigland akayLinear energy transferHadean venturesMust investPrivate placementBoard chairTeigland akayManaging partnerChief executive officerStern investor relationsநேரியல் ஆற்றல் பரிமாற்றம்வேண்டும் முதலீடு